Lyudmila V. Shishkina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lyudmila V. Shishkina has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
- Sergey K. Gorelyshev
Burdenko Neurosurgical Center
7 shared publications - Galina. A. Novichkova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela St., Moscow 117198, Russia
6 shared publications - Lyudmila I. Papusha
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
6 shared publications - Marina Vladimirovna Ryzhova
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia
6 shared publications - Alexander Karachunsky
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
5 shared publications - Andge Valiakhmetova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
5 shared publications
Latest Publications
- 14 April 2026
- Published by "MedINK" Publishing House in Russian journal of neurosurgery
- Vol. 28 (1)
Pituitary apoplexy – an urgent operation or a wait-and-see strategy?
Background. Pituitary tumors are a common pathology in neuro-oncology. They constitute 10 % of all intracranial tumors; and for a long time, they may not have any clinical manifestations. In situations where pituitary apoplexy is the first manifestation of the disease, the choice of optimal tactics is particularly relevant. Considering cases of spontaneous tumor resorption after pituitary apoplexy, the standard approach to this pathology as an exceptional urgent one requires revision. Aim. To review the treatment strategy of patients with pituitary apoplexy, identifying factors contributing to both tumor resorption and achievement of a better clinical result. After specification of the indications for surgery, to create an algorithm for treating patients with pituitary apoplexy. Materials and methods. The paper analyzes the results of treatment of 82 patients with pituitary apoplexy. Only 45 patients were operated on. In 37 patients, the need for surgery ceased during preparation. Results. Analysis of treatment results of 82 patients with pituitary apoplexy identified optimal tumor parameters and radiological characteristics for which the probability of spontaneous resorption is the highest: 89.2 % (33 out of 37) cases. The use of dexamethasone as part of therapy has shown to play a key role in achieving optimal results. The analysis of the data allowed us to formulate criteria for which a wait-and-see tactic in pituitary apoplexy can provide a result comparable to the surgical method of treatment and even surpassing it in terms of preservation of pituitary functions. Conclusion. As a result of the study, an algorithm for treatment of patients with pituitary apoplexy was proposed. The application of the proposed algorithm will allow, in some cases, to forego an emergency surgery and obtain a comparable clinical result with less risk for the patient.
- 14 April 2026
- Published by "MedINK" Publishing House in Russian journal of neurosurgery
- Vol. 28 (1)
Pituitary apoplexy – an urgent operation or a wait-and-see strategy?
Background. Pituitary tumors are a common pathology in neuro-oncology. They constitute 10 % of all intracranial tumors; and for a long time, they may not have any clinical manifestations. In situations where pituitary apoplexy is the first manifestation of the disease, the choice of optimal tactics is particularly relevant. Considering cases of spontaneous tumor resorption after pituitary apoplexy, the standard approach to this pathology as an exceptional urgent one requires revision. Aim. To review the treatment strategy of patients with pituitary apoplexy, identifying factors contributing to both tumor resorption and achievement of a better clinical result. After specification of the indications for surgery, to create an algorithm for treating patients with pituitary apoplexy. Materials and methods. The paper analyzes the results of treatment of 82 patients with pituitary apoplexy. Only 45 patients were operated on. In 37 patients, the need for surgery ceased during preparation. Results. Analysis of treatment results of 82 patients with pituitary apoplexy identified optimal tumor parameters and radiological characteristics for which the probability of spontaneous resorption is the highest: 89.2 % (33 out of 37) cases. The use of dexamethasone as part of therapy has shown to play a key role in achieving optimal results. The analysis of the data allowed us to formulate criteria for which a wait-and-see tactic in pituitary apoplexy can provide a result comparable to the surgical method of treatment and even surpassing it in terms of preservation of pituitary functions. Conclusion. As a result of the study, an algorithm for treatment of patients with pituitary apoplexy was proposed. The application of the proposed algorithm will allow, in some cases, to forego an emergency surgery and obtain a comparable clinical result with less risk for the patient.
- Open Access
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 63-79
Gliomas and glioneuronal tumors in children. Interpretation of molecular features
This review consolidates current knowledge on genetic alterations observed in pediatric glial and glioneuronal tumors of the central nervous system (CNS). Some of these alterations serve as diagnostic biomarkers, whereas others may inform the selection of targeted therapeutic strategies. Drawing on both diagnostic and clinical perspectives, the authors aim to facilitate a more comprehensive understanding of the WHO Classification of CNS Tumors and to promote interdisciplinary collaboration. This resource is intended to support accurate tumor classification, guide molecular testing, and aid in identifying actionable genetic targets. The content may be of practical value to pediatric neuro-oncologists, molecular pathologists, neuropathologists, and researchers involved in CNS tumor diagnostics and treatment. For user convenience, selected data are summarized in tables.
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 63-79
Open AccessGliomas and glioneuronal tumors in children. Interpretation of molecular features
This review consolidates current knowledge on genetic alterations observed in pediatric glial and glioneuronal tumors of the central nervous system (CNS). Some of these alterations serve as diagnostic biomarkers, whereas others may inform the selection of targeted therapeutic strategies. Drawing on both diagnostic and clinical perspectives, the authors aim to facilitate a more comprehensive understanding of the WHO Classification of CNS Tumors and to promote interdisciplinary collaboration. This resource is intended to support accurate tumor classification, guide molecular testing, and aid in identifying actionable genetic targets. The content may be of practical value to pediatric neuro-oncologists, molecular pathologists, neuropathologists, and researchers involved in CNS tumor diagnostics and treatment. For user convenience, selected data are summarized in tables.
- Open Access
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 85-94
Embryonal tumor of the central nervous system with PLAGL1 amplification: a case report and literature review
Embryonal tumor of the central nervous system (CNS) with PLAGL1/PLAGL2 amplification is a new type of CNS tumors in children, first described in 2023. They can be localized in any part of the CNS and, as their name suggests, are caused by the amplification of genes of the PLAG family. At present, this tumor is not yet defined as a separate type in the latest edition of the WHO classification in 2021. In the foreign literature, 27 cases of embryonal tumors of the CNS with PLAGL1 and PLAGL2 amplification in children have been described. A single standard of therapy has not yet been developed; the optimal treatment method is resection of the tumor, as well as polychemotherapy in combination with radiation therapy. This article presents a clinical case of a 2.5-year-old girl with an embryonal tumor with PLAGL1 amplification, describes in detail the treatment tactics and presents an analysis of cases previously described in international literature.
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 85-94
Open AccessEmbryonal tumor of the central nervous system with PLAGL1 amplification: a case report and literature review
Embryonal tumor of the central nervous system (CNS) with PLAGL1/PLAGL2 amplification is a new type of CNS tumors in children, first described in 2023. They can be localized in any part of the CNS and, as their name suggests, are caused by the amplification of genes of the PLAG family. At present, this tumor is not yet defined as a separate type in the latest edition of the WHO classification in 2021. In the foreign literature, 27 cases of embryonal tumors of the CNS with PLAGL1 and PLAGL2 amplification in children have been described. A single standard of therapy has not yet been developed; the optimal treatment method is resection of the tumor, as well as polychemotherapy in combination with radiation therapy. This article presents a clinical case of a 2.5-year-old girl with an embryonal tumor with PLAGL1 amplification, describes in detail the treatment tactics and presents an analysis of cases previously described in international literature.
- 5 February 2025
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 89 (1) , 83-93
Prolactin-secreting pituitary carcinomas with intra- and extracranial metastasis: case report and review
According to the modern WHO classification, pituitary carcinomas (or metastatic neuroendocrine pituitary tumors) are pituitary tumors with confirmed craniospinal and/or distant metastases. The main goal of histological analysis of pituitary carcinomas is to confirm pituitary origin of metastases. Treatment usually includes surgery and radiotherapy, dopamine agonists in maximum possible doses in case of prolactin-secreting pituitary carcinomas and chemotherapy with preferable temozolomide. Objective. To present the results of diagnosis and treatment of two patients with prolactin-secreting pituitary carcinomas. Material and methods. The authors describe 2 patients with prolactin-secreting pituitary carcinomas arising from drug-resistant aggressive prolactinomas with histologically confirmed metastases. In both cases, combined treatment included surgery, radio- and chemotherapy (cabergoline and temozolomide). Results. A 47-year-old patient underwent surgery, radio- and dopamine agonist therapy with subsequent regression of tumor growth in the follow-up period. However, progressive increase in prolactin concentration necessitated PET/CT with detection of multiple metastases in bones and lymph nodes. Temozolomide therapy led to temporary shrinkage of metastatic foci with subsequent progression. The second case was characterized by multiple brain and spinal cord metastases in a 47-year-old woman. Resection of intracranial metastasis and temozolomide therapy stabilized the disease and normalized serum prolactin throughout 2-year follow-up with subsequent progression. Conclusion. Pituitary carcinoma is a rare tumor with unfavorable prognosis. Treatment is currently not standardized and determined by available world experience regarding various chemotherapeutic drugs. Temozolomide is the most effective drug. However, short-term remission is usually followed by subsequent disease progression in most cases.
- 5 February 2025
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 89 (1) , 83-93
Prolactin-secreting pituitary carcinomas with intra- and extracranial metastasis: case report and review
According to the modern WHO classification, pituitary carcinomas (or metastatic neuroendocrine pituitary tumors) are pituitary tumors with confirmed craniospinal and/or distant metastases. The main goal of histological analysis of pituitary carcinomas is to confirm pituitary origin of metastases. Treatment usually includes surgery and radiotherapy, dopamine agonists in maximum possible doses in case of prolactin-secreting pituitary carcinomas and chemotherapy with preferable temozolomide. Objective. To present the results of diagnosis and treatment of two patients with prolactin-secreting pituitary carcinomas. Material and methods. The authors describe 2 patients with prolactin-secreting pituitary carcinomas arising from drug-resistant aggressive prolactinomas with histologically confirmed metastases. In both cases, combined treatment included surgery, radio- and chemotherapy (cabergoline and temozolomide). Results. A 47-year-old patient underwent surgery, radio- and dopamine agonist therapy with subsequent regression of tumor growth in the follow-up period. However, progressive increase in prolactin concentration necessitated PET/CT with detection of multiple metastases in bones and lymph nodes. Temozolomide therapy led to temporary shrinkage of metastatic foci with subsequent progression. The second case was characterized by multiple brain and spinal cord metastases in a 47-year-old woman. Resection of intracranial metastasis and temozolomide therapy stabilized the disease and normalized serum prolactin throughout 2-year follow-up with subsequent progression. Conclusion. Pituitary carcinoma is a rare tumor with unfavorable prognosis. Treatment is currently not standardized and determined by available world experience regarding various chemotherapeutic drugs. Temozolomide is the most effective drug. However, short-term remission is usually followed by subsequent disease progression in most cases.
- 15 January 2025
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 1,p. 9-21
Morphological changes in vestibular schwannomas after stereotac - tic radiosurgery and retrospective assessment of indications for tumor removal
Stereotactic radiosurgery (SRS) of vestibular schwannomas (VS) is an effective and safe treatment method, competitive with microsurgery (MS). However, given the possibility of pseudo-progression, if the tumor continues to grow after SRS, one of the methods of additional treatment is MS, which is associated with an increased risk of dysfunction of the acoustic-facial group. Given the risks associated with MS, the decision on surgical removal of VS after SRS should be justified, taking into account the timing of the possible course of pseudo-progression. Material: from 2005 to 2015, 541 patients received radiosurgical treatment on the Gamma Knife device for vestibular schwannoma. In 17 (3.1%) cases out of 541 patients after SRS, microsurgical removal of the VS was performed, of which in 7 cases (41.1%) the only indication for tumor removal was an increase in its volume on average 40.4 months after SRS. A repeated analysis of pathomorphological preparations was performed in 11 patients to assess the signs in the tumors indicating the presence or absence of true tumor growth (recurrence). Result: in the studied material after SRS, a complete absence of Antony A and Antony B patterns predominated (63.6%), in the remaining cases their individual elements were detected. Rarefaction of cellular structures was noted in all samples. Fibrosis of the tumor stroma was noted in all patients, often in combination with foci of angiomatosis. Severe or focal edema was detected in 81.8%. Thus, it was established that after SRS, despite the continued growth of the tumor, typical post-radiation changes dominate in morphological preparations, indicating the absence of the potential of VS for further true growth.
- 15 January 2025
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 1,p. 9-21
Morphological changes in vestibular schwannomas after stereotac - tic radiosurgery and retrospective assessment of indications for tumor removal
Stereotactic radiosurgery (SRS) of vestibular schwannomas (VS) is an effective and safe treatment method, competitive with microsurgery (MS). However, given the possibility of pseudo-progression, if the tumor continues to grow after SRS, one of the methods of additional treatment is MS, which is associated with an increased risk of dysfunction of the acoustic-facial group. Given the risks associated with MS, the decision on surgical removal of VS after SRS should be justified, taking into account the timing of the possible course of pseudo-progression. Material: from 2005 to 2015, 541 patients received radiosurgical treatment on the Gamma Knife device for vestibular schwannoma. In 17 (3.1%) cases out of 541 patients after SRS, microsurgical removal of the VS was performed, of which in 7 cases (41.1%) the only indication for tumor removal was an increase in its volume on average 40.4 months after SRS. A repeated analysis of pathomorphological preparations was performed in 11 patients to assess the signs in the tumors indicating the presence or absence of true tumor growth (recurrence). Result: in the studied material after SRS, a complete absence of Antony A and Antony B patterns predominated (63.6%), in the remaining cases their individual elements were detected. Rarefaction of cellular structures was noted in all samples. Fibrosis of the tumor stroma was noted in all patients, often in combination with foci of angiomatosis. Severe or focal edema was detected in 81.8%. Thus, it was established that after SRS, despite the continued growth of the tumor, typical post-radiation changes dominate in morphological preparations, indicating the absence of the potential of VS for further true growth.
- Open Access
- 29 November 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (3) , 22-40
Results of a multicenter study of the treatment of WNT medulloblastomas in children
Medulloblastomas of the WNT molecular group (MB-WNT) represent the smallest group of MB and account for only 10 % of the total. This molecular group is characterized by a favorable prognosis. Given the aggressive treatment regimens for MB, reducing the intensity of therapy for prognostically favorable tumors seems justified. Purpose of the study – to demonstrate the results of treatment of children with MB-WNT and to determine the impact on survival of various prognostic factors. The study included 85 patients with MB-WNT under the age of 18 who received treatment and were followed up from 1993 to 2022. Median age at diagnosis was 10 years (min – 3, max – 17). All patients had classical MB. Metastatic spread of the tumor at the time of diagnosis was detected in 18 (21.2 %) patients, the presence of a residual tumor according to postoperative magnetic resonance imaging – in 32 (37.7 %). Somatic mutations in the TP53 gene were detected in 10 (7.1 %) patients, in the CTNNB1 gene – in 79 (92.9 %), in the APC gene – in 5 (5.9 %), chromosome 6 monosomy – in 76 (89.4 %) children. At the time of the analysis, 74 (87.1 %) patients were alive, 11 (12.9 %) patients died, a relapse was diagnosed in 6 (7.1 %) patients, of which 5 died from disease progression, 1 patient is alive in the second remission. One patient in long-term remission developed secondary meningioma 20 years after the diagnosis of MB. The 10-year progression-free survival (PFS) was 0.92. 5-year overall survival (OS) was 0.90, 10-year – 0.86. The median OS is 112 months. When analyzing the sample of patients with MB-WNT in our study, PFS and OS were statistically significantly higher in girls without metastatic tumor spread, with total resection of the tumor, stratified into the low-risk group, and in the absence of a somatic mutation in the TP53 gene in the tumor tissue. In multivariate analysis, PFS was influenced by the stage of the disease and the presence of a somatic mutation in the TP53 gene in the tumor tissue; on OS – only the presence of a somatic mutation in the TP53 gene in the tumor tissue.
- 29 November 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (3) , 22-40
Open AccessResults of a multicenter study of the treatment of WNT medulloblastomas in children
Medulloblastomas of the WNT molecular group (MB-WNT) represent the smallest group of MB and account for only 10 % of the total. This molecular group is characterized by a favorable prognosis. Given the aggressive treatment regimens for MB, reducing the intensity of therapy for prognostically favorable tumors seems justified. Purpose of the study – to demonstrate the results of treatment of children with MB-WNT and to determine the impact on survival of various prognostic factors. The study included 85 patients with MB-WNT under the age of 18 who received treatment and were followed up from 1993 to 2022. Median age at diagnosis was 10 years (min – 3, max – 17). All patients had classical MB. Metastatic spread of the tumor at the time of diagnosis was detected in 18 (21.2 %) patients, the presence of a residual tumor according to postoperative magnetic resonance imaging – in 32 (37.7 %). Somatic mutations in the TP53 gene were detected in 10 (7.1 %) patients, in the CTNNB1 gene – in 79 (92.9 %), in the APC gene – in 5 (5.9 %), chromosome 6 monosomy – in 76 (89.4 %) children. At the time of the analysis, 74 (87.1 %) patients were alive, 11 (12.9 %) patients died, a relapse was diagnosed in 6 (7.1 %) patients, of which 5 died from disease progression, 1 patient is alive in the second remission. One patient in long-term remission developed secondary meningioma 20 years after the diagnosis of MB. The 10-year progression-free survival (PFS) was 0.92. 5-year overall survival (OS) was 0.90, 10-year – 0.86. The median OS is 112 months. When analyzing the sample of patients with MB-WNT in our study, PFS and OS were statistically significantly higher in girls without metastatic tumor spread, with total resection of the tumor, stratified into the low-risk group, and in the absence of a somatic mutation in the TP53 gene in the tumor tissue. In multivariate analysis, PFS was influenced by the stage of the disease and the presence of a somatic mutation in the TP53 gene in the tumor tissue; on OS – only the presence of a somatic mutation in the TP53 gene in the tumor tissue.
- Open Access
- 19 July 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (2) , 71-76
The principles of therapy for modern diagnosis of brain tumors in children, which determine the prescription of the drugs
Currently, the daily routine of a molecular pathologist is DNA methylation and RNA and DNA sequencing. The authors, from the standpoint of researchers and clinicians, explain the molecular methods used not only to diagnose brain tumors, but also to search for possible targets for therapy.
- 19 July 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (2) , 71-76
Open AccessThe principles of therapy for modern diagnosis of brain tumors in children, which determine the prescription of the drugs
Currently, the daily routine of a molecular pathologist is DNA methylation and RNA and DNA sequencing. The authors, from the standpoint of researchers and clinicians, explain the molecular methods used not only to diagnose brain tumors, but also to search for possible targets for therapy.
- 13 February 2023
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 87 (1) , 77-83
Intramedullary cervical abscess: a case report and literature review
Интрамедуллярные абсцессы спинного мозга представляют собой наиболее редкую форму инфекционного поражения структур центральной нервной системы. Представлен клинический случай успешного хирургического лечения пациентки с интрамедуллярным абсцессом шейного отдела спинного мозга, вызванного L. monocytogenes. Особенностью данного наблюдения является отсутствие первичного гнойного очага в организме и атипичный характер инфекционного агента. Больной было проведено хирургическое лечение по поводу интрамедуллярного абсцесса шейного отдела спинного мозга с последующей системной антимикробной терапией. В раннем послеоперационном периоде отмечался практически полный регресс неврологической симптоматики. В работе акцентируется внимание на строгом коллегиальном принятии решения в отношении клинико-инструментальной диагностики описываемого патологического состояния и выбора оптимальной тактики терапии указанной группы пациентов с интрамедуллярным абсцессом спинного мозга.
- 13 February 2023
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 87 (1) , 77-83
Intramedullary cervical abscess: a case report and literature review
Интрамедуллярные абсцессы спинного мозга представляют собой наиболее редкую форму инфекционного поражения структур центральной нервной системы. Представлен клинический случай успешного хирургического лечения пациентки с интрамедуллярным абсцессом шейного отдела спинного мозга, вызванного L. monocytogenes. Особенностью данного наблюдения является отсутствие первичного гнойного очага в организме и атипичный характер инфекционного агента. Больной было проведено хирургическое лечение по поводу интрамедуллярного абсцесса шейного отдела спинного мозга с последующей системной антимикробной терапией. В раннем послеоперационном периоде отмечался практически полный регресс неврологической симптоматики. В работе акцентируется внимание на строгом коллегиальном принятии решения в отношении клинико-инструментальной диагностики описываемого патологического состояния и выбора оптимальной тактики терапии указанной группы пациентов с интрамедуллярным абсцессом спинного мозга.
- 1 January 2023
- Published by Federal State Budgetary Institution "National Medical Research Center named after. V.A. Almazov" Ministry of Health of the Russian Federation" in Russian Neurosurgical Journal named after Professor A. L. Polenov
- Vol. 15 (1) , 132-138
DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR: A CASE REPORT AND REVIEW OF LITERATURE
- 1 January 2023
- Published by Federal State Budgetary Institution "National Medical Research Center named after. V.A. Almazov" Ministry of Health of the Russian Federation" in Russian Neurosurgical Journal named after Professor A. L. Polenov
- Vol. 15 (1) , 132-138
DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR: A CASE REPORT AND REVIEW OF LITERATURE
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (4) , 127-134
Long-term epilepsy-associated tumors
ЦЕЛЬ ИССЛЕДОВАНИЯ Суммировать данные о рентгенологической и гистологической диагностике доброкачественных опухолей, ассоциированных с эпилепсией, а также привести рекомендации по хирургическому лечению эпилепсии при данных опухолях. МАТЕРИАЛ И МЕТОДЫ Использованы статьи из базы медицинской литературы PubMed, а также собственные клинические данные. РЕЗУЛЬТАТЫ Доброкачественные глионейрональные опухоли являются второй по частоте причиной структурной фармакорезистентной эпилепсии у взрослых после склероза гиппокампа. Крайне медленный рост, локализация в коре головного мозга, наличие нейрональной ткани в строме опухоли и сопутствующая эпилепсия являются общими характеристиками этих новообразований. Сложность лечения глионейрональных опухолей заключается в сочетании эпилептологического и нейроонкологического аспектов. Эпилептогенная зона может выходить за пределы опухоли, поэтому ее изолированной резекции может оказаться недостаточно для прекращения приступов. ЗАКЛЮЧЕНИЕ С нейроонкологической точки зрения глионейрональные опухоли являются новообразованиями с очень низким пролиферативным потенциалом, однако необходима их тщательная дифференциальная диагностика с более агрессивными глиальными опухолями; эта задача может быть крайне сложной, но выполнимой методами гистологии и иммуногистохимии.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (4) , 127-134
Long-term epilepsy-associated tumors
ЦЕЛЬ ИССЛЕДОВАНИЯ Суммировать данные о рентгенологической и гистологической диагностике доброкачественных опухолей, ассоциированных с эпилепсией, а также привести рекомендации по хирургическому лечению эпилепсии при данных опухолях. МАТЕРИАЛ И МЕТОДЫ Использованы статьи из базы медицинской литературы PubMed, а также собственные клинические данные. РЕЗУЛЬТАТЫ Доброкачественные глионейрональные опухоли являются второй по частоте причиной структурной фармакорезистентной эпилепсии у взрослых после склероза гиппокампа. Крайне медленный рост, локализация в коре головного мозга, наличие нейрональной ткани в строме опухоли и сопутствующая эпилепсия являются общими характеристиками этих новообразований. Сложность лечения глионейрональных опухолей заключается в сочетании эпилептологического и нейроонкологического аспектов. Эпилептогенная зона может выходить за пределы опухоли, поэтому ее изолированной резекции может оказаться недостаточно для прекращения приступов. ЗАКЛЮЧЕНИЕ С нейроонкологической точки зрения глионейрональные опухоли являются новообразованиями с очень низким пролиферативным потенциалом, однако необходима их тщательная дифференциальная диагностика с более агрессивными глиальными опухолями; эта задача может быть крайне сложной, но выполнимой методами гистологии и иммуногистохимии.